Address
200 Clarendon Street
Boston, MA 02116
United States of America (the)
Phone
650 503 9095
Website
Sector
Healthcare
Industry
Biotechnology
Employees
152
First IPO Date
January 26, 2018
| Name | Title | Pay | Year Born |
| Chen Schor | Chief Executive Officer, President & Director | 953,668 | 1972 |
| Donald Healey | Chief Technology Officer | 606,337 | 1962 |
| Brian Nicholas Harvey | Chief Financial Officer | 611,141 | 1961 |
| Julie Maltzman | Chief Medical Officer | 622,198 | 1968 |
| Blake Aftab | Senior Vice President & Chief Scientific Officer | 731,122 | 1981 |
| Amy Locke | Chief Human Resource Officer | 0 | N/A |
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.